1. Home
  2. SANG vs IPHA Comparison

SANG vs IPHA Comparison

Compare SANG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SANG
  • IPHA
  • Stock Information
  • Founded
  • SANG 1984
  • IPHA 1999
  • Country
  • SANG Canada
  • IPHA France
  • Employees
  • SANG N/A
  • IPHA N/A
  • Industry
  • SANG Computer Software: Programming Data Processing
  • IPHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SANG Technology
  • IPHA Health Care
  • Exchange
  • SANG Nasdaq
  • IPHA Nasdaq
  • Market Cap
  • SANG 235.6M
  • IPHA 148.3M
  • IPO Year
  • SANG 2021
  • IPHA 2019
  • Fundamental
  • Price
  • SANG $7.01
  • IPHA $1.79
  • Analyst Decision
  • SANG
  • IPHA Strong Buy
  • Analyst Count
  • SANG 0
  • IPHA 1
  • Target Price
  • SANG N/A
  • IPHA $11.50
  • AVG Volume (30 Days)
  • SANG 7.6K
  • IPHA 779.8K
  • Earning Date
  • SANG 02-06-2025
  • IPHA 09-12-2024
  • Dividend Yield
  • SANG N/A
  • IPHA N/A
  • EPS Growth
  • SANG N/A
  • IPHA N/A
  • EPS
  • SANG N/A
  • IPHA N/A
  • Revenue
  • SANG $244,406,000.00
  • IPHA $36,202,722.00
  • Revenue This Year
  • SANG $3.36
  • IPHA N/A
  • Revenue Next Year
  • SANG $7.39
  • IPHA $101.65
  • P/E Ratio
  • SANG N/A
  • IPHA N/A
  • Revenue Growth
  • SANG N/A
  • IPHA N/A
  • 52 Week Low
  • SANG $2.50
  • IPHA $1.29
  • 52 Week High
  • SANG $7.20
  • IPHA $3.51
  • Technical
  • Relative Strength Index (RSI)
  • SANG 57.08
  • IPHA 45.92
  • Support Level
  • SANG $6.89
  • IPHA $1.64
  • Resistance Level
  • SANG $7.15
  • IPHA $1.87
  • Average True Range (ATR)
  • SANG 0.20
  • IPHA 0.12
  • MACD
  • SANG -0.02
  • IPHA -0.04
  • Stochastic Oscillator
  • SANG 51.28
  • IPHA 28.66

About SANG Sangoma Technologies Corporation

Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: